摘要
目的探讨胰腺癌患者血清中可溶性Endoglin的表达水平及其临床意义。方法应用酶联免疫吸附试验(ELISA)测定50例胰腺癌患者、30例胰腺炎患者和50例健康对照者血清中Endoglin水平,同时应用电化学发光免疫分析法测定CA-199,并进行比较分析。结果胰腺癌组、胰腺炎组和健康对照组血清中Endoglin水平分别是(5.68±0.91)、(3.75±0.77)、(3.55±0.65)μg/L。胰腺癌组Endoglin表达水平高于胰腺炎组和健康对照组(P<0.01)。在胰腺癌的诊断中Endoglin的阳性率为70%。结论血清Endoglin在胰腺癌中高表达,有助于胰腺癌的临床诊断。
Objective To investigate the expression level of serum soluble Endoglin in the patients with pancreatic carcinoma and its clinical significance.Methods The expression level of serum Endoglin was measured by ELISA in 50 health controls,30 pancreatitis patients and 50 cases of pancreatic carcinoma.At the same time the serum CA-199 level was detected by using electrochemiluminescence immunoassay.Results The serum Endoglin levels in the pancreatic carcinoma group,pancreatitis group and healthy control group were（5.68±0.91）,（3.75±0.77）,（3.55±0.65）μg/L respectively,the serum Endoglin level in the pancreatic carcinoma group was higher than that in the pancreatitis group and the healthy control group（P〈0.01）.In the diagnosis of pancreatic carcinoma,the positive rate of Endoglin was 70%.Conclusion Serum Endoglin is highly expressed in pancreatic carcinoma and conducive to its diagnosis.
出处
《检验医学与临床》
CAS
2015年第14期2041-2042,共2页
Laboratory Medicine and Clinic
